The BAP is a learned society and registered charity. It promotes research and education in psychopharmacology and related areas, and brings together people in academia, health services, and industry. Formed in 1974, it is the largest such national association in Europe, and the second largest in the world.

Read more about BAP

Benefits of BAP membership include:

• FREE subscription and access to the Journal of Psychopharmacology (published monthly online).
• Reduced registration fees for the annual Summer Meeting.
• Half price subscription to the Online CPD Resource.
• Eligibility for prizes and awards.
• Student bursaries for the BAP Summer Meeting and international conferences.
• Reduced registration fees for selected partner association events.
• 50% OFF Royal Society of Biology membership (Read more)
• BAP Newsletter.
• Voting for BAP Officers and Council (full members only).
• Being part of one of the largest national psychopharmacology associations in the world.

Meetings and Events

External Event

BAP Session

Joint Event

BAP Event

BAP Stand

All Events

24th June 2019	Cannabis Europa	Southbank Centre, London
30th June 2019	Summer Course on Mood, Aggression & Attraction	Villa Finaly
1st July 2019	RCPsych International Congress 2019	London Excel Centre, London

Articles

Report from the BAP at the BNA on ‘Mental Illness in Children and Adolescents’
By Mitul Mehta
Posted on 16th May 2019

Prof Mitul Mehta from the British Association of Psychopharmacology (BAP) teamed up with Elaine Snell from the International Neuroethics Society to convene a symposium entitled ‘Mental Illness in Children and Adolescents’ as part of the British Neuroscience Association (BNA) Festival of Neuroscience held in Dublin, April 14^th-17^th

SYMPOSIUM 5: New concepts in the co-morbidity of psychiatric disorders, eating disorders and obesity.
By Sarah Stuart
Posted on 3rd August 2018

Underlying metabolic disturbances are often ignored when treating psychiatric disorders and can even be exacerbated with treatments, but it is becoming more apparent that these metabolic issues may not arise a result of treatment, but may instead be pre-existing in psychosis.  This session echoed the theme of schizophrenia and its co-morbidity with eating disorders that […]

SYMPOSIUM 3: Microglia role in neuropsychiatric disease and its potential as a treatment target
By Ciaran Fitzpatrick
Posted on 30th July 2018

(chaired by Valeria Mondelli & Peter Talbot)   Given that clinical, genetic and pharmacological findings indicate that inflammatory molecules and their associated pathways are enhanced in neuropsychiatric disorders such as major depressive disorder and schizophrenia, Monday morning’s symposium 3 dealt with the importance of microglia cells in these disorders. Microglia are immune...

See more articles

Media

David Nutt
Psychedelics, addiction, and mental health
David talks to ABC Radio National about psychedelics, addiction, and mental health
24th February 2019

Stephen Lawrie
Hollywood past saves climber Hamish MacInnes from dementia death sentence
Stephen was quoted in the Times article about how Hamish MacInnes recovered from Dementia with the help of his films and books
22nd February 2019

Chris Alford
BBC Radio 5 Live Drive Time - Alcohol Hangover
Chris Alford was talking with Anna and Chloe on BBC Radio 5 Live Drive Time about alcohol hangovers following the recent publication of a study showing that whether beer or wine was drunk first had no effect on the resulting hangover.
8th February 2019

Stephen Lawrie
Film and Mental Illness
Stephen Lawrie talks about the portrayal of mental illnesses on film
21st January 2019

Mitul Mehta
MDMA Increases Cooperation and Recruitment of Social Brain Areas When Playing Trustworthy Players in an Iterated Prisoner's Dilemma
Mitul and his team found that participants on MDMA were more willing to cooperate than those given the placebo. Covered by: Live Science, Wired, Vice (German), IFL Science, CTV News.
9th January 2019

See more media

News

See more news